02 May 2023
-
11 March 2020
-
11 March 2020
Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy
– In PRESTO, almost all nurse participants (97.8%) reported a preference* for the Somatuline® Depot(lanreotide) redesigned pre-filled syringe compared with the syringe for long-acting release octreotide–CAMBRIDGE, Mass. March 11, 2020 — Ipsen Biopha...
-
14 December 2023
- 4 mins read
-
14 December 2023
- 4 mins read
Music and Medicine: Understanding the role of epigenetics in cancer research
Dr. Amauri Soares, VP Head of Early Development & Innovation Oncology at Ipsen usesmusic to explain the importance of understanding the genetics of cancer and how the emerging field ofepigenetics could unlock a new paradigm for precision medicine....
-
09 November 2022
-
09 November 2022
Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma
PARIS, FRANCE, 9 November 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced the Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint d...
-
22 September 2023
-
22 September 2023
-
12 May 2023
-
12 May 2023
-
23 May 2023
-
23 May 2023
-
12 May 2023
-
12 May 2023
-
12 May 2023
-
12 May 2023
-
12 May 2023
-
12 May 2023